Locations:

Encouraging 90-Day Results for Allogeneic CAR T-Cell Therapy for Progressive Multiple Sclerosis

Phase 1 trial of azer-cel reports good preliminary safety and efficacy

stylized illustration of a CAR T receptor

The first reported clinical evaluation of azer-cel, an allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapy for progressive multiple sclerosis (MS), indicated no high-grade toxicities, stable or improved Expanded Disability Status Scale (EDSS) scores, and good peripheral B-cell depletion and subsequent repopulation with early evidence of immune reset.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

These preliminary results of the TG-Azercel-101 trial (NCT06680037) were presented in a late-breaking oral session at the 10th Joint ACTRIMS/ECTRIMS Meeting by first author Daniel Ontaneda, MD, PhD, a neurologist with Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research.

“These early results are very reassuring,” says Dr. Ontaneda, who serves as principal investigator for the trial’s Cleveland Clinic site, which has recruited six patients thus far, among the most among the eight participating centers. “The allogeneic method of manufacturing CAR T cells has important advantages over the autologous method, so we hope to see it perform well with better scalability.”

A potential new avenue for progressive MS treatment

Although many good treatments are now available for MS, they are mostly ineffective against progressive disease, which involves accumulation of disability independent of relapse activity. Progressive MS is believed to be mediated in part by chronic inflammation that is mediated by B cells in the central nervous system, compartmentalized behind the blood-brain barrier and out of reach of current MS therapies.

CAR T-cell technology has revolutionized treatment of B-cell blood malignancies and is now being tested for treating a variety of autoimmune B cell-mediated diseases. Autologous CAR T-cell therapy involves collecting a patient’s T cells with leukapheresis, genetically modifying them with a CAR that targets B cells, then growing the CAR T-cell population ex vivo, a process that takes several weeks. When replaced back into the patient in a single infusion, the new CAR-T cells attack and deplete targeted B cells. In autoimmune disease, the hope is that naturally repopulating naïve B cells will allow for a reset, halting disease progression without the need for other therapies. Autologous CAR T-cell therapy is currently being tested for progressive MS in the Breakfree-2 phase 1 trial (NCT06220201), with encouraging results out to 26 weeks

Advertisement

In contrast, allogeneic (or so-called off-the-shelf) CAR T-cell therapy involves using healthy donor T cells to manufacture the CAR T cells. The CAR, containing a single chain variable fragment that binds to CD19 (a marker of B cells), is inserted at the T-cell receptor alpha constant (TRAC) locus using ARCUS (a gene editing platform derived from algae), a method aimed at disrupting the T-cell receptor and preventing graft-versus-host disease (GVHD).

Because allogeneic CAR T cells are premanufactured and frozen, patients can receive treatment almost immediately. Other advantages of this approach include more consistent product quality and scalable manufacturing.

More than 130 cancer patients have now received allogeneic azer-cel therapy, with no cases of GVHD reported.

Cohort and study design

The main objective of the phase 1, open-label TG-Azercel-101 trial is to determine the recommended dose of azer-cel for future clinical development. The cohort for these preliminary results consists of 26 patients: nine with primary progressive MS, 10 with nonactive secondary progressive MS and seven with active secondary relapsing MS.

Median age is 51.5 years (range, 36 to 59), with equal numbers of both sexes. All patients had disability progression independent of relapse activity in the 12 months before enrollment despite all using anti-CD20 therapy. Median follow-up was 4.9 months (range, 0.1 to 15.0 months), with one patient discontinuing early.

After discontinuation of disease modifying therapies, lymphodepletion was induced using bendamustine. Patients were then given a single infusion of azer-cel starting at a dose of 30 × 106 cells. Dose escalation rose to dose-level 6 (500 × 106 cells) for subsequent patients.

Advertisement

Patients were assessed for safety, function and pharmacokinetics, using periodic clinical testing, lumbar puncture and MRI. The primary outcome was assessment of dose-limiting toxicity in the first 28 days after treatment.

Safety outcomes

Major findings from the cohort of 26 patients include the following:

  • No instances of the following were reported: dose-limiting toxicities, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, GVHD or infections of ≥ grade 3.
  • Cytokine response syndrome was reported in two patients (7.7%) (grade 1 in one and grade 2 in the other).
  • Grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in two patients (7.7%).
  • Serious adverse events requiring hospitalization occurred in four patients (15.4%). These included arthritis, ICANS, post-lumbar puncture syndrome and dyspnea, all of which resolved.
  • Grade 3 or greater treatment-emergent adverse events occurred in 11 patients (42.3%) and mainly included lymphopenia related to bendamustine treatment.

“CAR T-cell therapy is usually tempered by safety issues, so we were very encouraged that azer-cel appears to be associated with milder toxicity than has been seen in the use of other CAR T-cell therapies for cancer and in experimental autologous CAR T-cell therapy for MS,” Dr. Ontaneda says. “Furthermore, we did not see any increased toxicity associated with escalating dose.”

Efficacy outcomes

Clinical outcomes at day 90 included improved or stable scores on the following tests:

  • EDSS in 16 of 18 patients (also in 7 of 8 patients at day 180 and 3 of 3 at day 270)
  • Timed 25-Foot Walk in 16 of 17 patients
  • Nine-Hole Peg Test in 17 of 18 patients
  • Symbol Digit Modalities Test in 14 of 18 patients
  • In addition, MRI lesions at day 60 were stable from baseline for all 22 patients tested.

Advertisement

“These data are remarkable, especially considering that patients had a lot of disability at baseline and were not taking disease-modifying treatments for MS throughout the trial,” Dr. Ontaneda notes.

B-cell activity

As has been seen in autologous CAR T-cell therapy, most patients (17/18) experienced a rapid reduction in CD19 B cells in peripheral blood following azer-cel infusion. At the same time, varicella zoster virus humoral immunity was preserved.

“Over the ensuing weeks and months, B-cell reconstitution was enriched for transitional and naïve phenotypes,” Dr. Ontaneda reports. “This is consistent with an immune reset, suggesting that this therapy could be used as a one-time infusion.”

Cerebrospinal fluid signals were also positive, with a reduction of CD19+ B cells. There was no increase in neurofilament light chains, and oligoclonal bands were unchanged or decreased at day 10 in 77% of patients.

What’s next?

“These early findings in a small cohort are very encouraging,” Dr. Ontaneda concludes. The TG-Azercel-101 trial will continue to enroll patients, escalate the dose to assess tolerability, and follow efficacy and pharmacokinetics for two years. There is a plan to expand enrollment for other autoimmune conditions, including myasthenia gravis and chronic inflammatory demyelinating polyradiculoneuropathy. Subsequent trials are expected to start once the optimal dose has been determined.

The study is sponsored by TG Therapeutics, Inc., which is developing azer-cel.

Advertisement

Related Articles

floating CAR T cell against background of other cells

Zola-Cel CAR T-Cell Therapy Shows Promising Initial Results in Multiple Sclerosis

Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26

portrait of Dr. Jeffrey Cohen against decorative background with podcast icon overlay
June 16, 2026/Neurosciences/Podcast

The Potential of CAR T-Cell Therapy in Multiple Sclerosis (Podcast)

Updates on this fast-evolving therapeutic landscape from a leading trialist

Older patients
July 17, 2025/Cancer/Blood Cancers

CAR T-Cell Therapy Safe & Effective for Octogenarians with B-Cell Lymphoma

Age alone should not rule out patients from potentially curative treatment

Dr. Melenhorst
November 8, 2024/Cancer/News & Insight

Study Reveals Actionable Findings for Improving CAR T-Cell Longevity in Patients with Acute Lymphoblastic Leukemia

Higher type 2 immunity observed in persistent CAR T cells

car T-cells
June 3, 2024/Cancer/Blood Cancers

CAR T-Cell Treatment Offers Hope for Richter Transformation

Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel

23-CNR-3791118-CQD-Hero-650×450 multiple myeloma car t cell therapy
April 19, 2023/Cancer/Innovations

79-Year-Old Patient with R/R Multiple Myeloma Achieves Complete Remission with CAR T-Cell Therapy

Minimal residual disease testing shows promising results

CAR T-cell therapy
April 5, 2023/Cancer/Blood Cancers

Insights About CAR T-Cell Therapy

Dispelling myths and sharing practical experiences

illustration of a bright clinical room with clinicians inside

Inside Our Neurological Institute’s Next-Generation Advanced Therapeutics Space

Combining customized care, research capabilities and flexibility for the future

Ad